Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of immunotherapies that target tumors specifically and have fewer side effects. The German Federal Agency for Disruptive Innovation SPRIND will provide funding for the work of Plectonic Biotech in the coming years.